Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practice.
Core dataset
Core outcome set
Domains
Measurement instruments
Vitiligo
e-Delphi
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
23 Jul 2022
23 Jul 2022
Historique:
received:
02
03
2022
accepted:
25
06
2022
entrez:
23
7
2022
pubmed:
24
7
2022
medline:
27
7
2022
Statut:
epublish
Résumé
There is a lack of consensus related to the collection of standardized data for individuals with vitiligo enrolled in clinical trials and registries as well as those seen in clinical practice which causes difficulty in accurately interpreting, comparing, and pooling of data. Several years ago, efforts to initiate work on developing core outcome sets were performed and a consensus was reached in 2015 on the first core domain set for vitiligo clinical trials. This project aims to further develop a core outcome set for vitiligo clinical trials as well as create internationally agreed-upon core outcome sets for registries and clinical practice. These core outcome sets will include a core domain set and a core measurement instruments set and will be supplemented by contextual factors, including baseline and treatment-related characteristics. In a preparatory exercise, the 2015 core domain set will be re-evaluated and will serve as the basis for the list of outcome domains used to initiate the consensus process. This project will consist of two parts. Part 1 will focus on the selection of a core domain set, or "what to measure" and contextual factors, for each setting based on electronic surveys (e-Delphi technique) and a conclusive consensus meeting by a large group of international stakeholders. Part 2 will include selection of core measurement instruments, or "how to measure," and measurement details (e.g., scale and timing) for the core domain sets and contextual factors agreed upon in part 1. Part 2 will be based on consensus meetings with stakeholders involved in part 1 and will be guided by C3 (CHORD-COUSIN Collaboration), Harmonising Outcome Measures for Eczema (HOME), COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN), and Outcome Measures in Rheumatology (OMERACT) recommendations including information on measurement properties of available instruments (systematic review and expert/patient opinion). At the end of part 2, all stakeholders involved will be invited to participate in a final meeting in which the ultimate core data sets (core outcome sets and contextual factors) will be presented and the dissemination plan and implementation goals will be defined. This project will harmonize data collection between clinical trials, registries, and clinical practices, facilitating new insights in vitiligo. This study is registered in the Core Outcome Measures for Effectiveness Trials (COMET) database and on the C3 (CHORD-COUSIN Collaboration) website.
Sections du résumé
BACKGROUND
BACKGROUND
There is a lack of consensus related to the collection of standardized data for individuals with vitiligo enrolled in clinical trials and registries as well as those seen in clinical practice which causes difficulty in accurately interpreting, comparing, and pooling of data. Several years ago, efforts to initiate work on developing core outcome sets were performed and a consensus was reached in 2015 on the first core domain set for vitiligo clinical trials.
METHODS/DESIGN
METHODS
This project aims to further develop a core outcome set for vitiligo clinical trials as well as create internationally agreed-upon core outcome sets for registries and clinical practice. These core outcome sets will include a core domain set and a core measurement instruments set and will be supplemented by contextual factors, including baseline and treatment-related characteristics. In a preparatory exercise, the 2015 core domain set will be re-evaluated and will serve as the basis for the list of outcome domains used to initiate the consensus process. This project will consist of two parts. Part 1 will focus on the selection of a core domain set, or "what to measure" and contextual factors, for each setting based on electronic surveys (e-Delphi technique) and a conclusive consensus meeting by a large group of international stakeholders. Part 2 will include selection of core measurement instruments, or "how to measure," and measurement details (e.g., scale and timing) for the core domain sets and contextual factors agreed upon in part 1. Part 2 will be based on consensus meetings with stakeholders involved in part 1 and will be guided by C3 (CHORD-COUSIN Collaboration), Harmonising Outcome Measures for Eczema (HOME), COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN), and Outcome Measures in Rheumatology (OMERACT) recommendations including information on measurement properties of available instruments (systematic review and expert/patient opinion). At the end of part 2, all stakeholders involved will be invited to participate in a final meeting in which the ultimate core data sets (core outcome sets and contextual factors) will be presented and the dissemination plan and implementation goals will be defined.
DISCUSSION
CONCLUSIONS
This project will harmonize data collection between clinical trials, registries, and clinical practices, facilitating new insights in vitiligo.
TRIAL REGISTRATION
BACKGROUND
This study is registered in the Core Outcome Measures for Effectiveness Trials (COMET) database and on the C3 (CHORD-COUSIN Collaboration) website.
Identifiants
pubmed: 35871019
doi: 10.1186/s13063-022-06497-1
pii: 10.1186/s13063-022-06497-1
pmc: PMC9308182
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
591Informations de copyright
© 2022. The Author(s).
Références
J Clin Epidemiol. 2011 Apr;64(4):395-400
pubmed: 21194891
Pigment Cell Melanoma Res. 2017 Jul;30(4):436-443
pubmed: 28379638
Arch Dermatol. 2012 Nov;148(11):1302-9
pubmed: 22986764
Trials. 2016 Sep 13;17(1):449
pubmed: 27618914
Int J Nurs Pract. 2012 Apr;18(2):188-94
pubmed: 22435983
J Appl Meas. 2010;11(3):304-14
pubmed: 20847477
Trials. 2014 Jun 25;15:247
pubmed: 24962012
Br J Dermatol. 2012 Oct;167(4):804-14
pubmed: 22591025
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Br J Dermatol. 2019 Mar;180(3):574-579
pubmed: 30030843
Qual Life Res. 2018 May;27(5):1147-1157
pubmed: 29435801
Pigment Cell Melanoma Res. 2015 May;28(3):363-9
pubmed: 25645179
J Invest Dermatol. 2015 Jan;135(1):24-30
pubmed: 25186228
Australas J Dermatol. 2019 Aug;60(3):e178-e185
pubmed: 30820942
Br J Dermatol. 2016 May;174(5):962-9
pubmed: 26686510
J Am Acad Dermatol. 2019 Jul;81(1):297-305
pubmed: 30878565
Qual Life Res. 2014 Aug;23(6):1733-41
pubmed: 24402179